Royal Bank of Canada’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-35
| Closed | – | – | 6848 |
|
|
2024
Q2 | $0 | Buy |
35
+14
| +67% | +$105 | ﹤0.01% | 7044 |
|
|
2024
Q1 | $0 | Sell |
21
-15
| -42% | -$82 | ﹤0.01% | 7010 |
|
|
2023
Q4 | $0 | Sell |
36
-96
| -73% | -$288 | ﹤0.01% | 7105 |
|
|
2023
Q3 | $0 | Sell |
132
-33
| -20% | -$750 | ﹤0.01% | 7076 |
|
|
2023
Q2 | $5K | Buy |
165
+63
| +62% | +$2.61K | ﹤0.01% | 6659 |
|
|
2023
Q1 | $5K | Hold |
102
| – | – | ﹤0.01% | 6552 |
|
|
2022
Q4 | $3K | Hold |
102
| – | – | ﹤0.01% | 6839 |
|
|
2022
Q3 | $7K | Hold |
102
| – | – | ﹤0.01% | 6577 |
|
|
2022
Q2 | $4K | Hold |
102
| – | – | ﹤0.01% | 6701 |
|
|
2022
Q1 | $5K | Hold |
102
| – | – | ﹤0.01% | 7239 |
|
|
2021
Q4 | $6K | Hold |
102
| – | – | ﹤0.01% | 7168 |
|
|
2021
Q3 | $5K | Sell |
102
-23
| -18% | -$1.21K | ﹤0.01% | 7122 |
|
|
2021
Q2 | $7K | Sell |
125
-504
| -80% | -$26.9K | ﹤0.01% | 6966 |
|
|
2021
Q1 | $37K | Sell |
629
-170
| -21% | -$12.8K | ﹤0.01% | 6066 |
|
|
2020
Q4 | $55K | Buy |
799
+50
| +7% | +$6.81K | ﹤0.01% | 5616 |
|
|
2020
Q3 | $190K | Sell |
749
-113
| -13% | -$23.1K | ﹤0.01% | 4589 |
|
|
2020
Q2 | $145K | Buy |
862
+13
| +2% | +$1.4K | ﹤0.01% | 4628 |
|
|
2020
Q1 | $59K | Buy |
849
+196
| +30% | +$15.3K | ﹤0.01% | 5068 |
|
|
2019
Q4 | $42K | Sell |
653
-23
| -3% | -$1.33K | ﹤0.01% | 5524 |
|
|
2019
Q3 | $39K | Buy |
676
+23
| +4% | +$1.36K | ﹤0.01% | 5219 |
|
|
2019
Q2 | $39K | Hold |
653
| – | – | ﹤0.01% | 5399 |
|
|
2019
Q1 | $42K | Buy |
653
+17
| +3% | +$967 | ﹤0.01% | 5252 |
|
|
2018
Q4 | $34K | Sell |
636
-2
| -0.3% | -$99 | ﹤0.01% | 5302 |
|
|
2018
Q3 | $36K | Buy |
638
+2
| +0.3% | +$121 | ﹤0.01% | 5388 |
|
|
2018
Q2 | $37K | Hold |
636
| – | – | ﹤0.01% | 5282 |
|
|
2018
Q1 | $30K | Buy |
636
+334
| +111% | +$16.8K | ﹤0.01% | 5287 |
|
|
2017
Q4 | $18K | Sell |
302
-1
| -0.3% | -$60 | ﹤0.01% | 5631 |
|
|
2017
Q3 | $18K | Buy |
303
+34
| +13% | +$2.2K | ﹤0.01% | 5998 |
|
|
2017
Q2 | $17K | Hold |
269
| – | – | ﹤0.01% | 5598 |
|
|
2017
Q1 | $17K | Buy |
269
+100
| +59% | +$5.2K | ﹤0.01% | 5706 |
|
|
2016
Q4 | $6K | Sell |
169
-600
| -78% | -$20.8K | ﹤0.01% | 6245 |
|
|
2016
Q3 | $28K | Hold |
769
| – | – | ﹤0.01% | 5408 |
|
|
2016
Q2 | $28K | Hold |
769
| – | – | ﹤0.01% | 5363 |
|
|
2016
Q1 | $30K | Buy |
769
+100
| +15% | +$3.67K | ﹤0.01% | 5333 |
|
|
2015
Q4 | $29K | Buy |
669
+200
| +43% | +$8.24K | ﹤0.01% | 5560 |
|
|
2015
Q3 | $16K | Buy |
469
+400
| +580% | +$18.8K | ﹤0.01% | 5654 |
|
|
2015
Q2 | $4K | Hold |
69
| – | – | ﹤0.01% | 6272 |
|
|
2015
Q1 | $4K | Hold |
69
| – | – | ﹤0.01% | 5783 |
|
|
2014
Q4 | $5K | Buy |
69
+33
| +92% | +$1.73K | ﹤0.01% | 5799 |
|
|
2014
Q3 | $2K | Buy |
+36
| New | +$2.22K | ﹤0.01% | 5788 |
|
Other funds holding BCLI
AC
LWM
WCG
AHB
RJA
Royal Bank of Canada's BCLI Position: Q3 2024 in Review
Royal Bank of Canada sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2024, closing a stake of 35 shares.
Royal Bank of Canada first reported a position in BCLI in Q3 2014 and held it in 40 quarters. The position peaked at $190K in Q3 2020. 38 funds tracked by Wall St. Rank hold BCLI as of Q3 2024.
- Royal Bank of Canada reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2024 after selling out during the quarter.
- Royal Bank of Canada sold 35 BRAINSTORM CELL THERAPUTC shares in Q3 2024.
- Royal Bank of Canada first reported a position in BRAINSTORM CELL THERAPUTC in Q3 2014 and held it in 40 quarters.
- Royal Bank of Canada's BRAINSTORM CELL THERAPUTC position peaked at $190K in Q3 2020.
- 38 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2024.
Based on Royal Bank of Canada's 13F filing for Q3 2024, filed 14 Nov 2024.